Press Release Actimed Therapeutics Announces Publication Of Successful S Pindolol Benzoate Acm 001 1 Phase 1 Study In The Journal Of Cachexia, Sarcopenia And Muscle
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Press Release Actimed Therapeutics Announces Publication Of Successful S Pindolol Benzoate Acm 001 1 Phase 1 Study In The Journal Of Cachexia, Sarcopenia And Muscle is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Actimed Therapeutics to Highlight Advancing Clinical Pipeline with New Data Presentations at 18th Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders
London, UK – 9th December 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on ... Read More
Actimed Therapeutics Announces Important Licensing Agreement with Mankind Pharma
The MarketWatch News Department was not involved in the creation of this content. -- Covers exclusive rights to S-pindolol, the novel therapy in development for the treatment of cachexia, in India and ... Read More
Actimed Therapeutics Announces Important Licensing Agreement with Mankind Pharma
Covers exclusive rights to S-pindolol, the novel therapy in development for the treatment of cachexia, in India and South Asia Represents a major step in the mission of Actimed to bring the first ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus